Reply to Cheng and Chuang

Variability of daptomycin minimum inhibitory concentrations for Enterococcus faecium when measured by reference broth microdilution and gradient diffusion tests

(2018) Shelley A. Campeau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamic Analysis of Daptomycin-Treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint

(2018) Lindsay M Avery et al.   CLINICAL INFECTIOUS DISEASES

Influence of Minimum Inhibitory Concentration in Clinical Outcomes ofEnterococcus faeciumBacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?

(2016) Bhavarth S. Shukla et al.   CLINICAL INFECTIOUS DISEASES

Association between Vancomycin Day 1 Exposure Profile and Outcomes among Patients with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis

(2015) Anthony M. Casapao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Vancomycin Exposure in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: How Much Is Enough?

(2014) Thomas P. Lodise et al.   CLINICAL INFECTIOUS DISEASES

Correlation between Mutations inliaFSRof Enterococcus faecium and MIC of Daptomycin: Revisiting Daptomycin Breakpoints

(2012) Jose M. Munita et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY